Applied research of a novel foot and mouth disease vaccine
Lead Participant:
CAMBIVAC LTD
Abstract
This application is for a Proof of Concept grant to see if it is feasible to overcome current
technical difficulties with a system that would potentially allow the production of improved
foot and mouth (FMD) vaccines without the use of live virus.
We propose to use advanced biotechnical techniques that could result in cheaper and more
effective vaccines without the risk of escape of live virus along the lines of the 2007 escape
from Pirbright in Surrey.
The foot and mouth vaccine market is divided in two: countries where vaccination is used to
control foot and mouth such as China, India, and Brazil; and those, such as the UK, Europe
and North America, where a stock of vaccine is kept should culling prove unable to control an
outbreak, total market estimated to be in excess of £350mill.
There is little or no cross-protection across the seven FMD serotypes (A, O, C, Asia 1, Sat 1,
Sat 2 and Sat 3) and a large number of subtypes requiring vaccines that are matched to
circulating field strains. We believe our technology will lead to the opportunity to
manufacture vaccines in the UK for export to the rest of the world where vaccination is used
to control foot and mouth, an opportunity not possible with the current technology which
would use live strains of exotic strains of foot and mouth.
We believe our approach could also be used to produce, without the risk of live virus escape,
more effective vaccines than those currently stockpiled in countries such as the UK for use in
conjunction with culling. The technologies allow for the rapid incorporation of emerging field
strain sequences and could also respond rapidly to the more damaging situation of a new
strain outbreak which is not possible with existing vaccine production methods.
FMD is one of the most economically and socially devastating animal diseases globally and
such a tool combined with other integrated strategies would have major economic and social
benefit to the UK, EU and many other regions of the world.
technical difficulties with a system that would potentially allow the production of improved
foot and mouth (FMD) vaccines without the use of live virus.
We propose to use advanced biotechnical techniques that could result in cheaper and more
effective vaccines without the risk of escape of live virus along the lines of the 2007 escape
from Pirbright in Surrey.
The foot and mouth vaccine market is divided in two: countries where vaccination is used to
control foot and mouth such as China, India, and Brazil; and those, such as the UK, Europe
and North America, where a stock of vaccine is kept should culling prove unable to control an
outbreak, total market estimated to be in excess of £350mill.
There is little or no cross-protection across the seven FMD serotypes (A, O, C, Asia 1, Sat 1,
Sat 2 and Sat 3) and a large number of subtypes requiring vaccines that are matched to
circulating field strains. We believe our technology will lead to the opportunity to
manufacture vaccines in the UK for export to the rest of the world where vaccination is used
to control foot and mouth, an opportunity not possible with the current technology which
would use live strains of exotic strains of foot and mouth.
We believe our approach could also be used to produce, without the risk of live virus escape,
more effective vaccines than those currently stockpiled in countries such as the UK for use in
conjunction with culling. The technologies allow for the rapid incorporation of emerging field
strain sequences and could also respond rapidly to the more damaging situation of a new
strain outbreak which is not possible with existing vaccine production methods.
FMD is one of the most economically and socially devastating animal diseases globally and
such a tool combined with other integrated strategies would have major economic and social
benefit to the UK, EU and many other regions of the world.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
Participant |
||
| CAMBIVAC LTD |
People |
ORCID iD |